Viewing StudyNCT06383572

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 8:27 PM
Last Modification Date: 2024-10-26 @ 3:27 PM
Study NCT ID: NCT06383572
Status: RECRUITING
Last Update Posted: 2024-06-28
First Post: 2024-04-22
Brief Title: Phase III Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of RelapseRefractory Myeloid Malignancies
Sponsor: MD Anderson Cancer Center
Organization: MD Anderson Cancer Center
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Lymphodepleting Chemotherapy
Myeloid Malignancies
Keywords: